Quince Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.07.22	Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 (Businesswire)
27.07.22	Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 (Businesswire)
21.06.22	Cortexyme : Preclinical Data Show Efficacy Of COR803 For Coronavirus Infections Treatment (RTTNews)
21.06.22	Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections (Businesswire)
13.06.22	Cortexyme Appoints June Bray to its Board of Directors (Businesswire)
20.05.22	Cortexyme Announces Completion Of Novosteo Acquisition (RTTNews)
20.05.22	Cortexyme Appoints Dr. Philip Low to Its Board of Directors (Businesswire)
20.05.22	Cortexyme Successfully Completes Acquisition of Novosteo (Businesswire)
13.05.22	Pre-market Movers: EBET, AFRM, CELU, FIGS, LLAP… (RTTNews)
10.05.22	Cortexyme Announces Agreement to Acquire Novosteo (Businesswire)
16.03.22	ROSEN, A LEADING LAW FIRM, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - CRTX (PR Newswire)
15.03.22	Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors (Businesswire)
14.03.22	Cortexyme to Present New GAIN Trial Data at AD/PD 2022 (Businesswire)
09.03.22	Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant Disorders (Businesswire)
08.03.22	Cortexyme Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Trial of COR588 (Businesswire)
16.02.22	SHAREHOLDER ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - CRTX (PR Newswire)
01.02.22	Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones (Businesswire)
01.02.22	Cortexyme Announces Change in Executive Leadership Team (Businesswire)
26.01.22	Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application (Businesswire)
27.10.21	Pre-market Movers: CXDC, CRTX, ANGN, GHSI, BIMI… (RTTNews)
08.07.21	Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat (Businesswire)
01.06.21	Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting (Businesswire)
26.05.21	Cortexyme to Present at Investor Conferences in June 2021 (Businesswire)
10.05.21	Cortexyme Provides Business Update and Reports First Quarter 2021 Results (Businesswire)
04.05.21	Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021 (Businesswire)
17.02.21	BLUE Hit By SCD Trial Blues, CRTX Plunges On Partial Hold, SESN To Face FDA In August (RTTNews)
16.02.21	Cortexyme Says FDA Places Partial Clinical Hold On Atuzaginstat (RTTNews)
31.12.20	So schätzen die Analysten die Cortexyme-Aktie im Dezember 2020 ein (finanzen.net)
30.06.20	Cortexyme-Aktie: Experten empfehlen Cortexyme im Juni mehrheitlich zum Kauf (finanzen.net)
14.02.20	Stock To Watch: Cortexyme (CRTX) (RTTNews)
12.12.19	Healthcare IPOs That Delivered Solid Returns In 2019 (RTTNews)
19.06.19	Biopulse: High-Flyers With Billion-Dollar Market Cap (RTTNews)
18.06.19	5 Top Gainers In Healthcare Sector (ARRY, SYBX, CRTX...) (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	121.15	2.19 %	K V
Logitech Intl	72.20	1.66 %	K V
Lonza Grp	526.60	1.00 %	K V
Swiss Re	129.35	0.82 %	K V
UBS Group	28.35	0.18 %	K V
Givaudan	3’901.00	-0.81 %	K V
Swiss Life Hldg	725.40	-1.12 %	K V
Holcim	89.78	-1.12 %	K V
Novartis	91.93	-1.87 %	K V
Sonova Hldg	306.20	-1.89 %	K V

Nachrichten zu Quince Therapeutics

Aktien Top/Flop

Meistgelesene Nachrichten